CD8A and neoplasm: Additionally, combining this treatment with Alb-IFNβ increased CD8+ and CD4+ T cell infiltration in the tumor microenvironment while reducing PD-1 expression on TILs and regulatory T cells, thereby enhancing the overall immune response (96).